Company research
PROTHENA CORP PUBLIC LTD CO
CIK 1559053Updated Sep 26, 2026
SecurityPRTA · NASDAQ · equity
Name history
Prothena Corp plc · through May 22, 2020Neotope Corp Ltd · through Oct 1, 2012
PRTA price & chart
Loading TradingView…
NASDAQ:PRTA on TradingView ↗About the company
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 326,804,000Source | 547,108,000Source | 696,382,000Source | 758,035,000Source |
| Property, Plant and Equipment, NetUSD | 2,144,000Source | 3,081,000Source | 3,836,000Source | 1,731,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 307,531,000Source | 471,388,000Source | 618,830,000Source | 710,406,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 0Source | 5,159,000Source | — |
| Assets, CurrentUSD | 315,193,000Source | 485,412,000Source | 639,282,000Source | 719,098,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,662,000Source | 14,024,000Source | 13,941,000Source | 8,692,000Source |
| Operating Lease, Right-of-Use AssetUSD | 8,125,000Source | 10,708,000Source | 12,162,000Source | 6,277,000Source |
| Other Assets, NoncurrentUSD | 482,000Source | 3,808,000Source | 6,349,000Source | 10,513,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 46,330,000Source | 60,182,000Source | 135,017,000Source | 135,993,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 538,000Source | 538,000Source | 537,000Source | 521,000Source |
| Additional Paid in CapitalUSD | 1,626,369,000Source | 1,588,729,000Source | 1,540,859,000Source | 1,454,524,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,346,433,000Source | -1,102,341,000Source | -980,031,000Source | -833,003,000Source |
| Stockholders' Equity Attributable to ParentUSD | 280,474,000Source | 486,926,000Source | 561,365,000Source | 622,042,000Source |
| Liabilities and EquityUSD | 326,804,000Source | 547,108,000Source | 696,382,000Source | 758,035,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 40,843,000Source | 48,501,000Source | 56,891,000Source | 50,147,000Source |
| Operating Lease, Liability, CurrentUSD | 2,886,000Source | 2,610,000Source | 1,114,000Source | 6,473,000Source |
| Accounts Payable, CurrentUSD | 5,875,000Source | 7,770,000Source | 25,391,000Source | 9,270,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,487,000Source | 8,233,000Source | 10,721,000Source | 0Source |
| Other Liabilities, NoncurrentUSD | — | — | 0Source | 553,000Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | — | 0Source | — |
| Deferred Revenue, CurrentUSD | 2,664,000Source | 8,850,000Source | 0Source | 11,442,000Source |
| Deferred Revenue, NoncurrentUSD | 0Source | 3,448,000Source | 67,405,000Source | 85,293,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 895,000Source | 893,000Source | 928,000Source | 744,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 37,640,000Source | 45,964,000Source | 40,914,000Source | 31,322,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 0Source | -5,159,000Source | 5,159,000Source | — |
| Deferred Income Tax Expense (Benefit)USD | 43,239,000Source | -9,346,000Source | -15,689,000Source | -11,133,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -163,580,000Source | -150,050,000Source | -133,906,000Source | -108,821,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -138,000Source | -298,000Source | -2,773,000Source | -464,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -139,000Source | 1,554,000Source | 45,103,000Source | 241,457,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 308,391,000Source | 472,248,000Source | 621,042,000Source | 712,618,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 931,000Source | 3,172,000Source | 1,554,000Source | 2,659,000Source |
| Additional Financial Items | ||||
| DepreciationUSD | 900,000Source | 900,000Source | 900,000Source | 700,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -104,000Source | 0Source | -15,000Source | -1,000Source |
| General and Administrative ExpenseUSD | 59,392,000Source | 67,199,000Source | 61,835,000Source | 49,900,000Source |
| Income Tax Expense (Benefit)USD | 43,263,000Source | -6,620,000Source | -13,452,000Source | -8,656,000Source |
| Net Income (Loss) Attributable to ParentUSD | -244,092,000Source | -122,310,000Source | -147,028,000Source | -116,949,000Source |
| Nonoperating Income (Expense)USD | 13,811,000Source | 25,631,000Source | 30,556,000Source | 5,952,000Source |
| Operating ExpensesUSD | 224,324,000Source | 289,718,000Source | 282,406,000Source | 185,462,000Source |
| Other Nonoperating Income (Expense)USD | -328,000Source | -185,000Source | -458,000Source | -397,000Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 1,907,000Source | 21,520,000Source | 17,841,000Source |
| Restructuring CostsUSD | 30,080,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 9,684,000Source | 135,157,000Source | 91,370,000Source | 53,905,000Source |
| Operating Income (Loss)USD | -214,640,000Source | -154,561,000Source | -191,036,000Source | -131,557,000Source |
| Other Nonoperating Income (Expense)USD | -328,000Source | -185,000Source | -458,000Source | -397,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -200,829,000Source | -128,930,000Source | -160,480,000Source | -125,605,000Source |
| Income Tax Expense (Benefit)USD | 43,263,000Source | -6,620,000Source | -13,452,000Source | -8,656,000Source |
| Net Income (Loss) Attributable to ParentUSD | -244,092,000Source | -122,310,000Source | -147,028,000Source | -116,949,000Source |
| Earnings Per Share, BasicUSD per share | -4.53Source | -2.27Source | -2.76Source | -2.47Source |
| Earnings Per Share, DilutedUSD per share | -4.53Source | -2.27Source | -2.76Source | -2.47Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 53,829,000Source | 53,772,000Source | 53,216,000Source | 47,369,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 53,829,000Source | 53,772,000Source | 53,216,000Source | 47,369,000Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 24,000Source | 2,726,000Source | 2,237,000Source | 2,477,000Source |
| General and Administrative ExpenseUSD | 59,392,000Source | 67,199,000Source | 61,835,000Source | 49,900,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -191,818,000Source | -129,602,000Source | — | — |
| Interest Income (Expense), NetUSD | 14,139,000Source | 25,816,000Source | 31,014,000Source | 6,349,000Source |
| Nonoperating Income (Expense)USD | 13,811,000Source | 25,631,000Source | 30,556,000Source | 5,952,000Source |
| Operating ExpensesUSD | 224,324,000Source | 289,718,000Source | 282,406,000Source | 185,462,000Source |
| Research and Development ExpenseUSD | 134,852,000Source | 222,519,000Source | 220,571,000Source | 135,562,000Source |
| Restructuring CostsUSD | 30,080,000Source | — | — | — |
Filing attachments
d38911dex991.htm · 8-K · 2025-08-27
EX-99.1 2 d38911dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibody Phase 1 ASCENT clinical program established proof-of-mechanism for PRX012 as a once-monthly, subcutaneous anti-amyloid beta antibody with high binding …
Read attachment ↗d42243dex991.htm · 8-K · 2025-08-06
EX-99.1 2 d42243dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE Prothena Announces that Novo Nordisk Will Advance Coramitug (formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program in 2025 Prothena to earn a c…
Read attachment ↗d13247dex991.htm · 8-K · 2025-06-16
EX-99.1 2 d13247dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson’s Disease Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression …
Read attachment ↗d891971dex991.htm · 8-K · 2025-05-23
EX-99.1 2 d891971dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint Birtamimab did not meet the primary endpoint of time to all-cause mortality or the secondary endpoints Birtamimab development will be discontinued, including stopping the open label extension of the AFFIRM-AL clinical trial Company will decrease ongoing operating expenses, including …
Read attachment ↗